Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Black Diamond Therapeutics (BDTX) Other Operating Expenses (2018 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Other Operating Expenses for 1 consecutive years, with $7.5 million as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Other Operating Expenses changed N/A year-over-year to $7.5 million, compared with a TTM value of $7.5 million through Sep 2020, changed N/A, and an annual FY2022 reading of $2.2 million, changed N/A over the prior year.
  • Other Operating Expenses was $7.5 million for Q4 2019 at Black Diamond Therapeutics, up from $2.5 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $7.5 million in Q4 2019 and bottomed at $2.5 million in Q3 2019.